Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Linda Lurslurchachai is active.

Publication


Featured researches published by Linda Lurslurchachai.


BMJ | 2011

Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study

Juan P. Wisnivesky; Cardinale B. Smith; Stuart Packer; Gary M. Strauss; Linda Lurslurchachai; Alex D. Federman; Ethan A. Halm

Objective To compare the survival and risk of serious adverse events in older patients with stages II-IIIA non-small cell lung cancer treated with or without postoperative platinum based chemotherapy. Design Observational cohort study. Setting Cases of lung cancer in Surveillance Epidemiology and End Results registry linked to Medicare files, 1992-2005, and follow-up data to December 2007. Participants 3324 patients aged more than 65 years with resected stages II-IIIA lung cancer. Main outcome measures Primary outcome was overall survival and secondary outcome was the rate of serious adverse events among older patients treated with or without adjuvant chemotherapy. Results Overall, 21% (n=684) of patients received platinum based chemotherapy. Analyses adjusted, stratified, or matched by propensity scores showed that chemotherapy was associated with improved survival (hazard ratio range 0.78-0.81). The beneficial effect of chemotherapy was also observed among patients treated with radiation therapy (0.75-0.77) or without radiation therapy (0.74-0.77); however, chemotherapy was not beneficial for patients aged 80 or more (1.32-1.46). Adjuvant chemotherapy was associated with an increased odds of serious adverse events (odds ratio 2.0, 95% confidence interval 1.5 to 2.6). Conclusions Platinum based adjuvant chemotherapy is associated with reduced mortality and increased risk of serious adverse events in older patients with stages II-IIIA lung cancer. The magnitude of the benefit is similar to that observed in randomised controlled trials carried out among selected patients.


Primary Care Respiratory Journal | 2011

Inhaler device, administration technique, and adherence to inhaled corticosteroids in patients with asthma.

Angkana Roy; Kayleigh Battle; Linda Lurslurchachai; Ethan A. Halm; Juan P. Wisnivesky

AIM To compare inhaled corticosteroid (ICS) inhaler type with user technique and ICS medication adherence among adults with asthma. METHODS We classified 270 adults into two groups by ICS device type: metered-dose inhaler (MDI) or dry powder inhaler (DPI). Inhaler technique was assessed using standardised checklists. Medication adherence was evaluated using the Medication Adherence Report Scale (MARS). Differences in inhaler technique and MARS score among patients using MDIs versus DPIs were evaluated. RESULTS Univariate analysis showed no difference in technique scores between the groups (p=0.46), but better ICS adherence among DPI users (p=0.001). In multivariable analysis, DPI use remained significantly associated with higher rates of adherence (OR 2.2; 95% CI 1.2 to 3.8) but not with inhaler technique (-0.2; 95% CI -0.5 to 0.1) after adjusting for potential confounders. CONCLUSIONS Type of inhaler device appears to be associated with adherence to asthma controller medications. Prospective studies are needed to elucidate further the potential effect of the type of ICS delivery device on asthma self-management.


Annals of Allergy Asthma & Immunology | 2010

Use of herbal remedies and adherence to inhaled corticosteroids among inner-city asthmatic patients

Angkana Roy; Linda Lurslurchachai; Ethan A. Halm; Xiu-Min Li; Howard Leventhal; Juan P. Wisnivesky

BACKGROUND Complementary and alternative medicines (CAM), such as herbal remedies, are widely used by patients with chronic diseases, such as asthma. However, it is unclear whether use of the herbal remedies is associated with decreased adherence to inhaled corticosteroids (ICSs), a key component of asthma management. OBJECTIVE To examine the association among use of herbal remedies, adherence to prescribed ICSs, and medication and disease beliefs. METHODS We surveyed 326 adults with persistent asthma who received care at 2 inner-city outpatient clinics. Patients were asked about CAM use (teas, herbs, and rubs) for the treatment of asthma in the prior 6 months. Medication adherence was assessed using the Medication Adherence Report Scale, a validated self-report measure. Univariate and multiple regression analyses were used to assess the relationship among herbal remedy use, adherence to ICSs, and medication and disease beliefs. RESULTS Overall, 25.4% (95% confidence interval, 20%-30%) of patients reported herbal remedy use. Univariate analyses showed that herbal remedy use was associated with decreased ICS adherence and increased asthma morbidity. In multivariable analysis, herbal remedy use was associated with lower ICS adherence (odds ratio, 0.4; 95% confidence interval, 0.2-0.8) after adjusting for confounders. Herbal remedy users were also more likely to worry about the adverse effects of ICSs (P = .01). CONCLUSIONS The use of herbal remedies was associated with lower adherence to ICSs and worse outcomes among inner-city asthmatic patients. Medication beliefs, such as worry about ICS adverse effects, may in part mediate this relationship. Physicians should routinely ask patients with asthma about CAM use, especially those whose asthma is poorly controlled.


Chest | 2012

Racial and Ethnic Differences in Beliefs About Lung Cancer Care

Sirisha Jonnalagadda; Jenny J. Lin; Judith E. Nelson; Charles A. Powell; John Salazar-Schicchi; Steven M. Keller; Cardinale B. Smith; Linda Lurslurchachai; Ethan A. Halm; Howard Leventhal; Juan P. Wisnivesky

BACKGROUND Disparities in lung cancer treatment and palliative care are well documented. However,the mechanisms underlying these disparities are not fully understood. In this study, we evaluated racial and ethnic differences in beliefs and attitudes about lung cancer treatment and palliative care among patients receiving a new diagnosis of lung cancer. METHODS Patients were recruited from four medical centers in New York City and surveyed about their beliefs regarding lung cancer care, including disease-directed treatments, palliative and end-of-life care, and fatalistic and spiritual beliefs. We used univariate and multiple regression analyses to compare the distribution of beliefs among minority (black and Hispanic) and nonminority patients. RESULTS Of the 335 patients, 21% were black, 20% were Hispanic, and 59% were nonminority. Beliefs about chemotherapy and radiotherapy were similar across the three groups ( P > .05),whereas black patients were more likely to believe that surgery might cause lung cancer to spread( P =.008). Fatalistic beliefs potentially affecting cancer treatment were more common among both minority groups ( P ≤ .02). No signifi cant differences were found in attitudes toward clinician communication about cancer prognosis ( P > .05). However, both blacks and Hispanics were more likely to have misconceptions about advance directives and hospice care ( P ≤ .02). CONCLUSIONS Similarities and differences in beliefs about disease-directed treatment were observed between minority and nonminority patients with lung cancer. Minority patients hold more fatalistic views about the disease and misperceptions about advance care planning and hospice care. Further research is needed to assess the impact of these beliefs on decisions about lung cancer care and patient outcomes.


Journal of Thoracic Oncology | 2013

Evaluating beliefs associated with late-stage lung cancer presentation in minorities

Cara Bergamo; Jenny J. Lin; Cardinale B. Smith; Linda Lurslurchachai; Ethan A. Halm; Charles A. Powell; John Schicchi; Steven M. Keller; Howard Leventhal; Juan P. Wisnivesky

Introduction: Minority patients in the United States present with later stages of lung cancer and have poorer outcomes. Cultural factors, such as beliefs regarding lung cancer and discrimination experiences, may underlie this disparity. Methods: Patients with a new diagnosis of lung cancer were recruited from four medical centers in New York City. A survey, using validated items, was conducted on the minority (black and Hispanic) and nonminority patients about their beliefs regarding lung cancer, fatalism, and medical mistrust. Univariate and logistic regression analyses were used to compare beliefs among minorities and nonminorities and to assess the association of these factors with late-stage (III and IV) presentation. Results: Of the 357 lung cancer patients, 40% were black or Hispanic. Minorities were more likely to be diagnosed with advanced-stage lung cancer (53% versus 38%, p = 0.01). Although beliefs about lung cancer etiology, symptoms, and treatment were similar between groups (p > 0.05), fatalistic views and medical mistrust were more common among minorities and among late-stage lung cancer patients (p < 0.05, for all comparisons). Adjusting for age, sex, education, and insurance, minorities had increased odds of advanced-stage lung cancer (odds ratio: 1.79; 95% confidence interval, 1.04–3.08). After controlling for fatalism and medical mistrust, the association between minority status and advanced stage at diagnosis was attenuated and no longer statistically significant (odds ratio: 1.56; 95% confidence interval, 0.84–2.87). Conclusions: Fatalism and medical mistrust are more common among minorities and may partially explain the disparities in cancer stage at diagnosis. Addressing these factors may contribute to reducing disparities in lung cancer diagnosis and outcomes.


Journal of Asthma | 2010

Perennial allergen-specific immunoglobulin E levels among inner-city elderly asthmatics.

Paula J. Busse; Linda Lurslurchachai; Hugh A. Sampson; Ethan A. Halm; Juan P. Wisnivesky

Background. The role of allergen sensitization has been well established among children and young adults with asthma. Some studies have suggested that allergens play a less important role among older patients with asthma. However, whether older asthmatics have a lower prevalence of allergen sensitization than younger adults remains controversial. The aim of this study was to access the prevalence of sensitization to indoor allergens in older compared to younger inner-city adults with persistent asthma. Methods. The authors used data collected as part of a cohort study of inner-city adults with persistent asthma. Sensitization to indoor allergens (specifically Dermatophagoides pteronyssinus, D. farinae, cat, mouse, Aspergillus fumigates, Alternaria, German and American cockroaches) was evaluated by specific immunoglobulin E (IgE) antibodies measured from peripheral blood. Univariate and multiple regression analyses were used to compare ratios of sensitization according to age (≤35, 36–59, ≥60 years of age). Results. Of the 245 patients in the study, 19% were over the age of 60 years. Overall 73%, 61%, and 41% of patients ≤35, 36–59, and ≥60 years old, respectively were sensitized to at least one indoor allergen (p = .01). Multivariate analysis showed that patients ≥60 years of age were significantly less likely to be sensitized (odds ratio 0.32, 95% confidence interval 0.11 to 0.89) compared to younger adults after controlling for potential confounders. Conclusions. Allergen sensitization is less common in older patients with persistent asthma. However, sensitization to any indoor allergen is relatively frequent in the elderly. Physicians should consider routinely accessing exposure and sensitization to these allergens as part of the evaluation of older inner-city patients with persistent asthma.


Clinical Respiratory Journal | 2014

Metered dose inhaler technique among inner‐city asthmatics and its association with asthma medication adherence

Linda Lurslurchachai; Katherine Krauskopf; Angkana Roy; Ethan A. Halm; Howard Leventhal; Juan P. Wisnivesky

Inhaled medications, critical for asthma treatment, are self‐administered through metered dose inhalers (MDI). Asthma self‐management hinges on adherence to these medications and to proper MDI technique.


European Respiratory Journal | 2012

Radiotherapy and chemotherapy for elderly patients with stage I–II unresected lung cancer

Juan P. Wisnivesky; Marcelo Bonomi; Linda Lurslurchachai; Grace Mhango; Ethan A. Halm

Radiotherapy (RT) is the standard therapy for unresected stage I–II nonsmall cell lung cancer (NSCLC). Using population-based data, we compared survival and toxicity among unresected elderly patients treated with combined chemoradiotherapy (CRT) or RT alone. Using the Surveillance, Epidemiology and End Results (SEER) registry (National Cancer Institute, Bethesda, MD, USA) we identified 3,006 cases of unresected stage I–II NSCLC. We used propensity score methods to compare survival and rates of toxicity of patients treated with RT versus CRT. Overall, 844 (28%) patients received CRT. Adjusted analyses showed that CRT was associated with improved survival (hazard ratio 0.85, 95% CI 0.78–0.94). Combination therapy was also associated with better survival among stage I patients treated with intermediate complexity RT (HR 0.80, 95% CI 0.70–0.90); however, no difference in survival was observed among patients treated with complex RT. In stage II patients, CRT was associated with improved survival regardless of the RT technique (HR 0.61–0.72). CRT was associated with increased odds of toxicity. Despite increased toxicity, CRT may improve survival of elderly unresected patients with stage II disease as well as stage I NSCLC treated with intermediate RT complexity. Randomised trials are needed to clarify the balance of benefits and risk of CRT in unresected patients.


Respiratory Medicine | 2012

Barriers to adherence to COPD guidelines among primary care providers

Xavier Perez; Juan P. Wisnivesky; Linda Lurslurchachai; Lawrence C. Kleinman; Ian M. Kronish


Lung Cancer | 2012

Beliefs and attitudes about lung cancer screening among smokers

Sirisha Jonnalagadda; Cara Bergamo; Jenny J. Lin; Linda Lurslurchachai; Michael A. Diefenbach; Cardinale B. Smith; Judith E. Nelson; Juan P. Wisnivesky

Collaboration


Dive into the Linda Lurslurchachai's collaboration.

Top Co-Authors

Avatar

Juan P. Wisnivesky

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Ethan A. Halm

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jenny J. Lin

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Cardinale B. Smith

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Angkana Roy

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Charles A. Powell

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar

Grace Mhango

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge